These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24890357)

  • 1. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control.
    Wo JY; Childs SK; Szymonifka J; Mamon HJ; Ryan DP; Blaszkowsky LS; Kwak EL; Ferrone CR; Allen JN; Zhu AX; Wolpin BM; Chan JA; Abrams TA; McCleary NJ; Fernandez-Del Castillo C; Hong TS
    Pract Radiat Oncol; 2014; 4(2):e117-e123. PubMed ID: 24890357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
    Ma SJ; Hermann GM; Prezzano KM; Serra LM; Iovoli AJ; Singh AK
    Cancer Med; 2019 Mar; 8(3):939-952. PubMed ID: 30652417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
    Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Golden DW; Novak CJ; Minsky BD; Liauw SL
    Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
    Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
    Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
    Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival.
    Morganti AG; Cellini F; Buwenge M; Arcelli A; Alfieri S; Calvo FA; Casadei R; Cilla S; Deodato F; Di Gioia G; Di Marco M; Fuccio L; Bertini F; Guido A; Herman JM; Macchia G; Maidment BW; Miller RC; Minni F; Passoni P; Valentini C; Re A; Regine WF; Reni M; Falconi M; Valentini V; Mattiucci GC
    BMC Cancer; 2019 Jun; 19(1):569. PubMed ID: 31185957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol.
    Rocha FG; Hashimoto Y; Traverso LW; Dorer R; Kozarek R; Helton WS; Picozzi VJ
    Ann Surg; 2016 Feb; 263(2):376-84. PubMed ID: 25775069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer.
    Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Moon SH; Yoo T; Kim SS; Kim SH; Hong EK; Kim DY; Park JW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e853-9. PubMed ID: 21497455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.
    Cloyd JM; Chen HC; Wang X; Tzeng CD; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MHG
    Pancreas; 2019 Feb; 48(2):216-222. PubMed ID: 30629022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection.
    Naffouje SA; Sabesan A; Kim DW; Carballido E; Frakes J; Hodul P; Denbo JW; Malafa M; Fleming J; Hoffe S
    J Gastrointest Surg; 2022 Feb; 26(2):376-386. PubMed ID: 34506031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
    Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
    Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
    [No Abstract]   [Full Text] [Related]  

  • 18. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.
    Yuan Z; Naghavi AO; Tang D; Kim Y; Ahmed KA; Dhillon J; Giuliano AR; Spiess PE; Johnstone PA
    World J Urol; 2018 Sep; 36(9):1431-1440. PubMed ID: 29589134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
    Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
    Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.